Yorkshire and the Humber Specialised Commissionning Group Board Meeting - 24th September 2010 Decision Summary for PCT Boards 1. Policies:
General Commissioning Policies for Medicines and Treatments The following four policies were approved for adoption by the SCG:-
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours - To be not routinely funded, in accordance with
Capecitabine for the treatment of advanced gastric cancer - To be routinely funded in
Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia - To be routinely fun
Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer - Update to regional policy 08/10 to reflect recently published
Evidenced-Based Commissioning (EBC) - Policies The following policies were approved for adoption by the SCG (category 2 in the EBC list)
Armour Thyroid (thyroid tablets USP, Forrest Pharmaceuticals) and other non – UK licensed products - (Hypothyroidism)
Bevacizumab (Avastin, Roche) – (Metastatic Colorectal Cancer)
Botulinum toxin type A (botox, Allergan; and all other brands) – (Hyperhidrosis)
Botulinum toxin A (Available as Botox (allergen), Vistabel (Allergen), Dysport (Ipsen), Xeomin (Merz pharma), Azzalure (Galderma) – (Overactive Bladder)
Botulinum toxin type A (Available as Botox (Allergen), Vistabel (Allergen), Dysport (Ipsen), Xeomin (Merz pharma), Azzalure (Galderma) – (Prophylaxis of Migraine)
Botulinum toxin A (Available as Botox (Allergen), Vistabel (Allergen), Dysport (Ipsen), Xeomin (Merz pharma), Azzalure (Galderma Ltd) – (Anal Tissues)
Cetuximab (Erbitux, Merck) – (Metastatic Colorectal Cancer)
Co-careldopa 2000mg/500mg intestinal gel for administration via PEG tube – (Parkinson’s Disease)
Penile Prostheses – (Erectile Dysfunction)
Gemcitabine IV infusion (Gemzar, Eli Lilly) Capecitabine 150mg or 500mg tablets (Xeloda, Roche) – (Pancreatic Cancer)
Infliximab – (Hidradenitis Supportiva)
C:\DOCUME~1\whitej\LOCALS~1\Temp\DecisionSummarySheet240910.doc 1
Mecasermin (Increlex, Ipsen) – (Growth Failure)
Sacral Nerve Stimulation [SNS] (Sacral Nerve Neuromodulation) – (Urinary retention/urinary urge incontinence/faecal incontinence/chronic constipation)
Spinal Cord Stimulation (neuromodulation) – (Intractable Chronic Pain)
(b) The following policies were approved for adoption by the constituent PCTs of the Yorkshire & the Humber SCG unless a PCT is able to inform the SCG why they should not adopt a specific policy (category 3 in the EBC list). Fesoterodine 4mg or 8mg tablets (Tovias, Pfizer Ltd) – (Overactive Bladder Syndrome) Testosterone Patch 300mg/24 hours twice weekly (Intrinsa, Proctor & Gamble Pharmaceuticals – (Hypoactive Sexual Disire Disorder) Ivabradine (Procoralan, Servier) – (Angina) Liraglutide 6mg/mL pre-filled pen (Victoza, Novo-Nordisk – (Type 2 Diabetes Mellitus) Nebivolol 5mg tablets (Nebilet, A, Menarini Pharma UK – (Chronic Heart Failure) NuvaRing (11.7 mg etonogestrel and 2.7 mg ethinylestradiol) Organon – (Contraception) Prostaglandin Analogues (latanoprost, bimatoprost, travaprost, tafluprost) – (Glaucoma) Proton Pump Inhibitors (Omeprazole, Lansoprazole, Esomeprazole, Rabeprazole) – (Dyspesia) Ranolazine Modified release tablets (Ranexa; A Menarini Pharma UK) – (Angina) Retapamulin 1% - (Skin Infections) Sitagliptin 100mg tablets (Januvia, MSD) – (Diabetes) Solifenacin 5mg and 10mg (Vesicare, Astellas Pharma Ltd) – (Urge Incontinence) Buprenorphone/naloxone (Suboxone/Schering Plough – (Opioid Dependence) Prolonged release oxycodone & naloxone tablets (Targinact, Napp Pharmaceuticals) – (Severe Pain) Ulipristal Acetat 30mg (EllaOne HRA Pharma UK) – (Contraception) Vildagliptin 50mg tablets (Galvus, Novartis) – (Diabetes) Reimbursement of Living Donor Expenses Policy This policy recommended by the Yorkshire & the Humber Renal Network was approved for adoption by the SCG. 2. Governance Yorkshire & the Humber SCG Annual Report 2009/10 It was agreed that:- The annual report be presented to PCT Boards. Strengthening SCG Board Governance Arrangements **PCT Boards are recommended to adopt the Establishment Agreement and Scheme of Delegation in respect of the Yorkshire and the Humber Specialised Commissioning Group**.
C:\DOCUME~1\whitej\LOCALS~1\Temp\DecisionSummarySheet240910.doc 2
Topical Amitriptyline and Ketamine in Neuropathic PainMary Elizabeth Lynch,* Alexander John Clark,† Jana Sawynok,‡ and Michael J. Sullivan§ Abstract: Twenty eight subjects with refractory, moderate to severe peripheral neuropathic pain participated in an open label prospective trial examining perceived analgesic effect, patient satisfac- tion, and safety of topical amitriptyline 2%/ketamine
Osteoporosis Canada statement on esophageal cancer and bisphosphonate use We are aware of a recent publication that reports on the association between oral bisphosphonate use and esophageal cancer1. We recognize that you might find these reports concerning. Osteoporosis Canada takes your concerns seriously and we will continue to be vigilant in order to inform you about the latest rese
Yorkshire and the Humber Specialised Commissionning Group